ArticleCell biochemistry and biophysics2026
Immunoinformatics-Driven Identification of Conserved Multi-Epitope Vaccine Candidates from PDI Protein of Leishmania Donovani for Visceral Leishmaniasis.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Visceral leishmaniasis (VL), caused by Leishmania donovani, continues to pose a public health challenge, particularly in the Indian subcontinent. This warrants the need for a prophylactic vaccine; hence, a comprehensive immunoinformatics approach was employed to identify B-cell and T-cell epitopes from the parasite’s Protein Disulfide Isomerase (PDI), a known virulence factor. Strong CD8 + epitopes (RTAAGIASY, FLATAVLDY, SVAAFVEKY) and a CD4 + epitope (VKRFLATVA) were selected based on MHC-binding affinity, immunogenicity, and conservation across Leishmania species. In addition, four linear B-cell epitopes were predicted using six classical algorithms. All selected epitopes were confirmed to be non-allergenic and non-toxic. Molecular docking and 100 ns molecular dynamics simulations demonstrated high-affinity binding and structural stability of HLA-epitope complexes, particularly FLATAVLDY with HLA-B∗15:01. These findings support the feasibility of designing a multi-epitope subunit vaccine targeting PDI for long-term VL control.
Indexed as
Identifiers
41739320What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.